BRTX BioRestorative Therapies, Inc.
XNASStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
What changed
Recent filings, trades and moves- Nov 25 Reports earnings
- Nov 12 8-K: Director or officer change

- Industry (SIC)
- SERVICES-MISC HEALTH & ALLIED SERVICES, NEC (8090) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 14
- List Date
- 1997-12-22
- CIK
- 0001505497
- Next Earnings
- 2026-11-25
- EPS Forecast
- ($2.60) (1 est.)
- Headquarters
- Melville, NY
- Homepage
- https://www.biorestorative.com
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection wit…
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -19.48% | 8.09% | -5.23% | 59.73% | -6.56% | 7.31% |
| Feb | -- | 37.97% | -10.06% | -35.19% | -35.59% | -80.14% | -24.60% |
| Mar | -- | -8.08% | 21.86% | -8.00% | 17.88% | 27.27% | 10.19% |
| Apr | -- | -23.41% | 13.47% | 1.43% | -1.12% | -21.02% | -6.13% |
| May | -- | 2.03% | 26.21% | -8.76% | -1.40% | 104.89% | 24.59% |
| Jun | -- | -34.22% | -17.57% | 57.36% | -7.47% | -7.48% | -1.88% |
| Jul | -- | -9.93% | -36.76% | -22.73% | -9.82% | -46.91% | -25.23% |
| Aug | -- | 7.55% | -23.88% | 7.19% | 30.50% | 2.27% | 4.73% |
| Sep | -- | 2.16% | -22.17% | 12.45% | -16.18% | -41.25% | -13.00% |
| Oct | -- | -4.41% | -4.35% | -1.27% | 7.69% | -38.31% | -8.13% |
| Nov | -14.53% | -5.25% | 6.67% | -1.92% | -28.09% | -11.49%* | -9.10% |
| Dec | -25.30% | -17.66% | -5.95% | -4.67% | 12.98% | -- | -8.12% |
| Total | -36.15% | -61.26% | -49.72% | -29.25% | -5.58% | -93.84% | -45.97% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report: BRTX
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 6/10)
Key Drivers:
- Bearish technical indicators, including MACD and RSI
- High volatility and beta relative to the market
- Recent negative news sentiment and lack of earnings data
Primary Risks:
- Continued price decline due to bearish momentum
- Increased volatility and potential for sharp moves
Investment Thesis: BRTX is a high-risk stock with significant technical and fundamental challenges. While recent positive news headlines provide some support, the overall trend remains bearish. Investors should exercise caution and consider hedging strategies or reevaluating their investment position.
Recent News Sentiment Impact: The recent positive news sentiment has provided some support to the stock price, but the impact is limited given the bearish technical indicators and high volatility.
Technical Analysis
Trend Direction:
- Short-term: BEARISH
- Medium-term: BEARISH
- Long-term: NEUTRAL (trend unclear)
Support/Resistance Levels:
- Lower band: $2.83 (Bollinger Bands)
- Middle band: $3.98 (SMA 50)
- Upper band: $5.12 (Bollinger Bands)
Momentum Signals: RSI: 24.29 (oversold), MACD: -0.55 / Signal: -0.08 / Histogram: -0.47 (bearish), RSI momentum: -1.43
Volume Analysis: Volume SMA 20: 22660.56, On-Balance Volume (OBV): 42931204.17, Volume Rate of Change: 71.07%
News & Sentiment Analysis
Recent Headlines Summary:
- Positive news headlines highlighting company's advancements in regenerative spine program and bio-cosmeceuticals
- Neutral news headlines related to public offering and conference participation
- No negative news headlines found
Sentiment Assessment: Aggregate news sentiment: POSITIVE ( weighted average of positive headlines)
Catalyst Identification: No immediate or near-term catalysts identified, but the company's advancements in regenerative spine program could provide a medium-term catalyst.
Market Narrative: The positive news sentiment and company advancements are not sufficient to overcome the bearish technical indicators and high volatility. The market narrative remains neutral-to-bearish.
Risk & Volatility Assessment
Risk Interpretation: Beta: 1.64 (high-risk stock relative to the market)
Volatility Regime: High volatility - stock moves more than the market
Options Market Signals: IV rank: N/A, put/call ratios: N/A, unusual activity: N/A
Downside Protection: Support levels: $2.83 (Bollinger Bands), risk management considerations: stop-loss at $3.00
Market Context & Positioning
Sector Performance: Relative strength vs sector/market: NEUTRAL
Institutional Activity: Volume patterns suggesting institutional interest: MIXED
Correlation Analysis: How stock moves relative to market (R-squared interpretation): 0.15 (high correlation)
Relative Valuation: Position within trading range: BEARISH (stock below its middle band)
Key Levels & Action Items
Critical Price Levels:
- Support: $2.83 (Bollinger Bands)
- Resistance: $3.98 (SMA 50)
Breakout/Breakdown Levels: None identified
Time-Sensitive Catalysts: No immediate or near-term catalysts identified, but the company's advancements in regenerative spine program could provide a medium-term catalyst.
Risk Management: Stop-loss at $3.00, position sizing considerations: reduce exposure or consider hedging strategies
BRTX Options Activity & IV Rank
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
IV(call wing) − IV(ATM), in vol pointsThe same measure on the upside: how the OTM call is priced against the at-the-money strike.
- Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
- Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Loading the implied volatility surface…
Loading the implied volatility smile…
Risk Metrics
Analysis Details
Data Points: 251
Period: 252 trading days
High volatility - stock moves more than market
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $103K | #5795 of 6285 | +14.5% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
BRTX Institutional Ownership (13F)
Filings for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
BRTX Insider Trading (Form 4)
Latest: 2025-10-20| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2025-10-20 | Lance Alstodt | President, CEO, COB | Award (A) | +15,625 | $1.60 | $25.0K | EDGAR |
| 2025-10-20 | Francisco Silva | VP of Research and Development | Award (A) | +11,719 | $1.60 | $18.8K | EDGAR |
| 2025-02-19 | David A Rosa | Director | Grant (A) | +52,632 opt | — | EDGAR | |
| 2025-02-19 | Lance Alstodt | President, CEO, COB | Award (A) | — | — | EDGAR | |
| 2025-02-19 | Nickolay V. Kukekov | Director | Grant (A) | +52,632 opt | — | EDGAR | |
| 2025-02-19 | Robert Eugene Kristal | Chief Financial Officer | Award (A) | — | — | EDGAR | |
| 2025-02-19 | Patrick F. Williams | Director | Grant (A) | +52,632 opt | — | EDGAR | |
| 2025-02-19 | Francisco Silva | VP of Research and Development | Award (A) | — | — | EDGAR | |
| 2024-11-05 | Dale Broadrick | 10%+ Owner | Sell (S) | −1,112 | $1.58 | -$1.8K | EDGAR |
| 2024-04-10 | Francisco Silva | VP of Research and Development | Buy (P) | +8,308 | $1.23 | $10.2K | EDGAR |
| 2024-03-20 | Lance Alstodt | President, CEO, COB | Tax (F) | −17,633 | $1.39 | -$24.5K | EDGAR |
| 2024-03-20 | Francisco Silva | VP of Research and Development | Tax (F) | −17,193 | $1.39 | -$23.9K | EDGAR |
| 2024-02-15 | Nickolay V. Kukekov | Director | Grant (A) | +79,646 opt | — | EDGAR | |
| 2024-02-15 | Robert Paccasassi | VP, QA and Reg Compliance | Grant (A) | +219,298 opt | — | EDGAR | |
| 2024-02-15 | Robert Eugene Kristal | Chief Financial Officer | Award (A) | — | — | EDGAR |
BRTX Insider Holdings
3 insiders · @ $1.31| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Lance Alstodt | President, CEO, COB | 9,375 | $12.3K | $124.9K | 39 | 2025-10-20 |
| 2 | Francisco Silva | VP of Research and Development | 9,176 | $12.0K | $116.4K | 21 | 2025-10-20 |
| 3 | Robert Eugene Kristal | Chief Financial Officer | 400 | $524 | $45.0K | 8 | 2025-02-19 |
BRTX Board & Officers
As of SEC filings through Jul 30, 2026Directors 6
- Lance Alstodt · listed since Nov 2020
- Jatinder Dhaliwal · since Jun 10, 2026
- Katharyn Field · since Jun 10, 2026
- Mika Grasso · since Jun 10, 2026
- Esha Randhawa · since Jul 13, 2026
- Steven Collier Brown · since Jul 14, 2026
Officers 1
- Lance Alstodt · President, CEO, COB · listed since Nov 2020
10% owners 1
- Lance Alstodt · listed since Oct 2025
Changes in the last 10 years (34)
| Jul 14, 2026 | Steven Collier Brown became a director |
| Jul 13, 2026 | The company announced the departure of David A Rosa from the board in an SEC filing |
| Jul 13, 2026 | Esha Randhawa became a director |
| Jun 10, 2026 | The company announced the departure of Patrick F. Williams from the board in an SEC filing |
| Jun 10, 2026 | The company announced the departure of Nickolay V. Kukekov from the board in an SEC filing |
| Jun 10, 2026 | Mika Grasso became a director |
| Jun 10, 2026 | Katharyn Field became a director |
| Jun 10, 2026 | Jatinder Dhaliwal became a director |
| Oct 20, 2025 | Lance Alstodt first listed as a 10% owner in an SEC filing |
| Oct 20, 2025 | Francisco Silva reported in an SEC filing no longer being a director |
| Oct 20, 2025 | Francisco Silva reported in an SEC filing no longer being VP of Research and Development |
| Feb 19, 2025 | Nickolay V. Kukekov first listed as a director in an SEC filing |
| Mar 20, 2024 | Lance Alstodt no longer listed as a 10% owner in SEC filings |
| Mar 20, 2024 | Francisco Silva no longer listed as a 10% owner in SEC filings |
| Feb 15, 2024 | Nickolay V. Kukekov reported in an SEC filing no longer being a director |
| Feb 17, 2023 | Lance Alstodt first listed as a 10% owner in an SEC filing |
| Feb 17, 2023 | Francisco Silva first listed as a 10% owner in an SEC filing |
| Nov 4, 2022 | Robert Paccasassi listed as VP, QA and Reg Compliance (previously VP, Quality and Compliance) in SEC filings |
| Nov 8, 2021 | Lance Alstodt no longer listed as a 10% owner in SEC filings |
| Nov 8, 2021 | Francisco Silva no longer listed as a 10% owner in SEC filings |
| Nov 4, 2021 | Robert Eugene Kristal became Chief Financial Officer |
| Nov 4, 2021 | Patrick F. Williams became a director |
| Nov 4, 2021 | David A Rosa became a director |
| Mar 19, 2021 | Lance Alstodt first listed as a 10% owner in an SEC filing |
| Mar 19, 2021 | Francisco Silva first listed as a 10% owner in an SEC filing |
| Mar 18, 2021 | Nickolay V. Kukekov became a director |
| Nov 24, 2020 | Lance Alstodt listed as President, CEO, COB (previously EVP and Chief Strategy Officer) in SEC filings |
| Nov 24, 2020 | Lance Alstodt first listed as a director in an SEC filing |
| Nov 24, 2020 | Francisco Silva first listed as a director in an SEC filing |
| Mar 26, 2019 | Mark Weinreb no longer listed as a 10% owner in SEC filings |
| Feb 19, 2019 | Dale Broadrick became a 10% owner |
| Oct 15, 2018 | Lance Alstodt became EVP and Chief Strategy Officer |
| Aug 21, 2018 | Robert Paccasassi became VP, Quality and Compliance |
| Jan 16, 2018 | Adam D. Bergstein became SVP, Planning and Business Dev |
- Prev
- 1
Not reported recently (12)
- Robert Eugene Kristal · Last reported as Chief Financial Officer in an SEC filing dated Feb 19, 2025
- Dale Broadrick · Last reported as a 10% owner in an SEC filing dated Nov 5, 2024
- Robert Paccasassi · Last reported as VP, QA and Reg Compliance in an SEC filing dated Feb 15, 2024
- Mark Weinreb · Last reported as a director in an SEC filing dated Sep 6, 2019
- Paul Jude Tonna · Last reported as a director in an SEC filing dated Sep 3, 2019
- A. Jeffrey Radov · Last reported as a director in an SEC filing dated Aug 29, 2019
- Robert B Catell · Last reported as a director in an SEC filing dated Mar 27, 2019
- Mandy D. Clyde · Last reported as VP of Operations in an SEC filing dated Mar 26, 2019
- Charles S. Ryan · Last reported as a director in an SEC filing dated Mar 25, 2019
- John M Desmarais · Last reported as a director in an SEC filing dated Mar 25, 2019
- Adam D. Bergstein · Last reported as SVP, Planning and Business Dev in an SEC filing dated Jan 19, 2018
- Edward L. Field · Last reported as President brtxDISC Division in an SEC filing dated Jul 14, 2017
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-12 | Director or officer change | EDGAR |
| 2026-10-09 | Director or officer change | EDGAR |
| 2026-09-11 | Director or officer change | EDGAR |
| 2026-09-02 | Shareholder rights change · Bylaws or fiscal year change · Regulation FD disclosure | EDGAR |
| 2026-09-02 | Auditor change · Director or officer change | EDGAR |
| 2026-08-25 | Listing standards notice | EDGAR |
| 2026-08-14 | Other events | EDGAR |
| 2026-07-16 | Director or officer change | EDGAR |
| 2026-06-12 | Director or officer change | EDGAR |
| 2026-06-12 | Material agreement · Director or officer change | EDGAR |
| Filing Date | Accession | Link |
|---|
| Filing Date | Accession | Link |
|---|
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $3,030 | — | 2026-10-31 |
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
BRTX vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| FMS Fresenius Medical Care AG | $10.9B | — | — | −14.3% | 37 |
| DVA DaVita Inc. | $10.2B | 11.5 | +5.9% | +36.1% | 43 |
| SHC Sotera Health Company Common Stock | $4.7B | 27.1 | +6.9% | −8.2% | 38 |
| PGNY Progyny, Inc. Common Stock | $2.7B | 32.5 | +5.5% | +37.8% | 15 |
| AGL agilon health, inc. | $1.5B | — | +2.0% | +423.6% | 6 |
| VMD Viemed Healthcare, Inc. Common Shares | $333M | 22.7 | +21.8% | +19.5% | 36 |
| QIPT Quipt Home Medical Corp. Ordinary Shares | $162M | — | +8.3% | +3.9% | — |
| PARK Park Dental Partners, Inc. Common Stock | $105M | — | — | +23.7% | — |
| BRTX BioRestorative Therapies, Inc. Common St | $2M | — | — | −94.6% | — |
| Peer median | $2.1B | 24.9 | +6.4% | +21.6% | 36 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.